MAPT and Cognitive impairment: Additionally, it was found that ARB use in people with normal cognition or mild cognitive impairment (MCI) was associated with lower levels of tau and phosphorylated tau [32, 34] and higher levels of Aβ1–42 in cerebrospinal fluid [34], and with decreased risk of dementia [34] when compared to other antihypertensive medication users (Table 2).